What are the precautions for using Pemigatinib

Pemigatinib is the world's first targeted therapy for cholangiocarcinoma for the treatment of adult patients with advanced, metastatic or unresectable cholangiocarcinoma who have received at least one prior systemic therapy and have been tested to have FGFR2 fusion or rearrangement.

What are the precautions for using Pemigatinib

There is a potential risk of Pemigatinib during treatment, that is, it may cause retinal pigment epithelial detachment. When this eye disease occurs, it can further lead to visual disturbance symptoms such as blurred vision, floaters-like floaters in vision, or flashes of light in front of the eyes.

During the clinical trial phase of Pemigatinib, routine optical coherence tomography was not included in the monitoring process to proactively screen and detect those cases of RPED that did not yet show significant symptoms. This monitoring gap means that there is a lack of definitive data and a clear understanding of the actual incidence of asymptomatic RPED after Pemigatinib.

Patients who are receiving Pemigatinib and potential patient groups considering the use of the drug need to be extra aware of this potential risk and closely monitor their eye health under the guidance of a physician. As soon as any abnormal vision or uncomfortable symptoms occur, you should seek medical attention immediately and inform your doctor that you are taking Pemigatinib so that necessary tests and interventions can be taken in time.

Guidance on the use of Pemigatinib

The following is guidance on the use of Pemigatinib.

1. Dosage

Typically, the recommended dose of Pemigatinib is 13.5 mg orally daily for 1 day for 14 days, followed by 7 days off in a 21-day cycle. Patients should strictly follow the doctor's guidance before taking the medication, and do not change the dose or stop the medication at will.

2. How to take the pills

Tablets should be swallowed whole, not crushed, chewed, split, or dissolved. This helps to maintain the stability and effectiveness of the drug.

Precautions for special drug users of Pemigatinib

1. Pregnant and lactating women

Pemigatinib can cause harm to the fetus, so pregnant and breastfeeding women should avoid using this drug. Women and men of childbearing age should use effective contraception during and for a certain period of time after treatment.

2. Elderly patients

Older patients may need to adjust their dose or pay more attention to monitoring when taking Pemigatinib, as they may have decreased physical function.

【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.